Item 2.02. Results of Operations and Financial Condition.

On January 9, 2023, Pacific Biosciences of California, Inc. (the "Company") issued a press release providing a business update and announcing certain unaudited preliminary financial results for the fourth quarter ended December 31, 2022 (the "Press Release"). A copy of the Press Release (other than the specific information incorporated by reference pursuant to Item 8.01 of this Current Report on Form 8-K) is furnished hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.




Item 8.01.  OTHER EVENTS.

The information set forth in the Press Release, solely to the extent such information references the orders for 76 Revio systems received by the Company in the fourth quarter, the Company's anticipated timing for the commercial launches of the Revio and Onso systems, and the Company's expectations for preliminary fourth quarter revenue and preliminary cash, cash equivalents and investments balance as of December 31, 2022, together with the paragraph set forth under the heading "Forward-looking statements", is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.

The portions of the Press Release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the Press Release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Because the Company's financial statements as of and for the quarter ended December 31, 2022 have not yet been finalized or audited and remain subject to change, the Company's final results for such periods may differ materially from the unaudited preliminary financial information included in the Press Release. Accordingly, you should not place undue reliance on the unaudited preliminary financial information included in the Press Release.




ITEM 9.01.                                             FINANCIAL STATEMENTS AND
                                                       EXHIBITS.

5

(d)           Exhibits.

Exhibit No.   Description

99.1            Press Release issued by Pacific Biosciences of California,
              Inc., dated January 9, 2023

104           Cover Page Interactive Data File (embedded within the Inline
              XBRL document)



                                       ?

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses